DNA vaccination is a novel means of inducing humoral and cellular immune responses capable of protecting hosts against a variety of infectious challenges. It is based on the in vivo expression of antigens after injection of the encoding genetic sequence, incorporated in a bacterial plasmid (1) . DNA vaccination has been successfully employed in an effort to combat leishmaniasis, a disease with considerable morbidity and mortality, which threatens millions of people worldwide (2) . The development of a Th 1 immune response, characterized by secretion of IFN-'Y by CD4+ T cells is prerequisite for the control of parasite multiplication in the tissues of the infected host (3) (4) . This results in the amelioration of the disease outcome, since it prevents the destructive inflammation observed at the site of the infectious challenge, which eventually results in severe necrosis. DNA vaccination has the characteristic ability to trigger Th 1 immune responses, the magnitude of which is largely determined by the route of DNA delivery, the intrinsic properties of the plasmid utilized and the sub-cellular localization of the encoded antigenic protein (1) . A number of reports have experimentally addressed the use of Leishmania genes in the context of DNA vaccination (5) . The most common and best-characterized antigenic sequences used so far are those of the LACK protein and the gp63 major glycoprotein (6-9), both of which are capable of protecting genetically susceptible BALB/c mice from infection with L. major, and control the disfiguring inflammatory reaction. However, the protection accomplished when the latter was used, was not optimal, as only a minority of animals was protected from subsequent infectious challenge with parasites (6) (7) (8) (9) (10) . This could be due to a sub-optimal Thl polarization, a problem that can be efficiently dealt with by the use of immunomodulatory molecules or by targeting of the protein of interest to selected cellular compartments (1) .
The injection of plasmids encoding molecules such as IL-12 and CD40L has often proved beneficial for the induction and maintenance of a strong Th 1 immune response (11) . CD40-CD40L interactions play key roles in driving Th 1 responses, since they are potent inducers ofIL-12 secretion from antigenpresenting cells (APCs) (12) (13) . The concurrent administration of plasmids encoding CD40L amplifies both cellular and humoral responses to the antigen of choice, and greatly influences CD4+ T cell polarization towards a Th 1 phenotype (14) . Moreover, selective targeting of the antigen of interest to the intracellular membrane or extracellular compartment has been shown to have a major impact on the development of Th 1 and Th2 populations and the expansion of antigenspecific CTLs (15) . Even though the membrane and intracellular localization of the antigens is classically thought to result in stronger Th 1 immune responses, there are examples of secreted forms of proteins, which induce adequate IFN-)' secretion (16) . Furthermore, they are probably able to trigger significant CD4+T cell proliferation since they generally provide sufficient quantity of antigen to the APCs (17) (18) .
In this report we describe an effort to optimize a DNA vaccination against L. major infection using the gp63 DNA, in order to restrain the inflammatory reaction at the experimentally infected footpad. To this end, we used a truncated, secreted form of gp63 and a plasmid construct that encoded the CD40L sequence.
MATERIALS AND METHODS

Animals
BALB/c mice were obtained from the breeding unit ofInstitut Pasteur Hellenique. Experimental animals were maintained under specific pathogen-free conditions, receiving a diet of commercial food pellets and water ad libitum. Immunizations were performed in female mice, 6 to 8 weeks of age.
Plasmid construction and purification
Total RNA was isolated from early stationary phase LV39 promastigotes using the RNeasy Mini Kit (Qiagen, GE) and were reversed transcribed. The gp63 cDNA was isolated from the total cDNA pool by PCR amplification. Primers used in the amplification step were designed based on a previously described sequence oftheL. major NIH S strain gp63 gene (EMBL GenBank Data Libraries Accession number Y00647). Two EcoRI sites were introduced by point-mutagenesis at the 5' and 3' ends of the gp63 cDNA. Primer sequence was: 5'TCGCCACCAGAATTCACTGCCCACAGCG3' and 5'TAC TGG AAT TCA CCT GCA CGC TAG CCG TGC GTG TGG3'. The isolated PCR product was then inserted into pBS KS+/-(Stratagene) at the EcoRI site. The product was sequenced using the KS and SK primers. Partial sequences of the gp63 cDNA are presented in Fig.1 and have been submitted to the EMBL GenBank Data Libraries under the accession number AY484446. The gp63 cDNA was' then subcloned into pcDNA3 vector (Invitrogen, CA) at the EcoRI site. Plasmid DNA was isolated by alkaline lysis of transformed E. coli cultures and purified by double banding cesium chloride gradient ultra centrifugation. The product had a 2601280 OD ratio that ranged from 1.8 to 2.0 and had negligible amounts of endotoxin.
A plasmid encoding the murine CD40L cDNA in a pORF vector was also purchased from Invivogen. Plasmid isolation from batch cultures of transformed E. coli and its purification using double banding cesium chloride gradient ultra centrifugation were performed as described above.
Parasites and challenge infection of mice
The strain MRHO/SU/59/P of L. major (LV39) was used in all experiments. Promastigotes were grown at 25°C, in Dulbecco' s modified Eagle medium (Gibco, Paisley, Scotland) supplemented with 10 mM HEPES (Gibco), Sx l O? M 2-Me, 2 mM L-glutamine (Sigma, Germany), 45 mM sodium pyruvate (Gibco), 24 mM NaHC0 3 (Gibco), 100 units/ml penicillin, 100 g/ml streptomycin and 10% fetal bovine serum, FBS (Gibco). For challenge infection, stationary phase LV39 promastigotes were isolated by centrifugation, washed extensively and resuspended in a volume of 20 fLI of PBS before being administered in the right footpad subcutaneously.
Immunization protocol
Mice were vaccinated in the ear with 100 u.g of plasmid DNA suspended in 30 fLI of sterile PBS intradermally (i.d.). Mice were boosted 3 weeks later with the same amount of plasmid DNA injected in the rump i.d. Two weeks after the second vaccination, immunized and control mice received a challenge infection as described above. Lesion progression was monitored weekly by measuring footpad thickness of the infected and the contralateral footpad, using a dial caliper (Kory Seiky MFG. Co. Ltd, Japan). Results are expressed in mm.
Statistical analysis
The unpaired Student's t-test was used to determine differences between vaccinated and non-vaccinated mice. Differences were considered statistically significant when p<O.05.
RESULTS
Vaccination ofsusceptible BALB/c mice with a plasmid encoding the truncated form of gp63 does not modify the disease outcome
In the initial experiment, we examined the ability of the plasmid encoding the truncated form of gp63, which lacks the gp anchor and is produced in a non-membrane retained form, to reduce the inflammatory swelling of the L. major infected footpads. We found that mice vaccinated with the gp63 plasmid had increased inflammatory lesions compared to the ones present in non-vaccinated mice and control vaccinated mice with antisense cDNA for gp63 (Fig. 2) . Inflammatory lesions were presented earlier in the group of mice vaccinated with the gp63-encoding plasmid, and their progression was accelerated. The inflammatory footpad swelling was continuously increased in both experimental groups, and was accompanied by severe tissue necrosis.
Co-injection of a plasmid encoding CD40L reverses the detrimental effect ofgp63 and results in apartial suppression ofthe inflammatory reaction
When we co-injected a plasmid encoding CD40L in mice that received the plasmid encoding gp63 , we observed a considerable amelioration of the disease outcome, as the inflammatory swelling was reduced in 60% of vaccinated mice (Fig. 3) . On the other hand, CD40L given together with a plasmid encoding the reverse sequence of gp63 did not result in a similar reduction of the inflammatory swelling, demonstrating that the outcome of vaccination was dependent on the gp63 gene.However, therest40% of mice vaccinated with the combination of the gp63 cDNA and CD40L had steadily progressing inflammatory lesions as the ones observed in the group receiving only the gp63-expressing plasmid, which were also accompanied by early tissue necrosis. Thi s indicates that there is a wide variation of the host responses to DNA vaccination even within a genetically homogeneous inbred mouse strain. In total four out of eleven mice receiving the gp63/ CD40L combination of plasmids showed complete unre sponsiveness to treatment and although the majority had an improved clinical course of disease, it is clear that implementation of vaccination strategies in the clinic would require careful designing and exhaustive pre-clinical testing.
DISCUSSION
Studies on DNA vaccinations where gp63 is used resulted in partial reduction of the destructive inflammatory reaction caused by challenge infection with L. major (6, 10) . These data have been interpreted on the basis of either the sub-optimal priming of Thl CD4+ T lymphocytes, or the development of CD8+T lymphocyte subsets instead of a vigorous CD4+response. Th 1immune responses are associated with reduced and transient inflammatory reaction in the site of cutaneous L. major infection, whereas Th2 responses result in severe inflammation and tissue necrosis (3) (4) .
In order to optimize a DNA vaccination strategy based on the use of the gp63 cDNA sequence, we initially used a truncated form of gp63 that does not include the Asn-577. This results in a lack of the GPI-anchor, which leads to the targeting of the translated protein to the endoplasmic reticulum and allows its secretion (19) . Secreted forms of proteins have been considered to induce a Th2 differentiation in parallel to the Th 1 (15) . However, there are reports in which extracellular localization resulted in sufficient IFN-')' secretion and, most importantly, triggered vigorous CD4+ T cell proliferation instead of CD8+T cell multiplication (16) (17) (18) . We thus decided to elaborate on the outcome of a DNA vaccination where the truncated gp63 was used. We found that this form of the protein resulted in an exacerbation of inflammatory lesions compared to the non-vaccinated animals, supporting the notion that secreted proteins indeed favor Th2 immune responses.
Molecules like IL-12 and CD40L have central roles in the induction of a host-protective Th 1 immune response, so they are generally considered beneficial when used as adjuvants in experimental vaccinations against L. major (11-14, 20-21) . However, DNA vaccination with IL-12 used as an adjuvant has given inconsistent results (22) (23) . We thus chose to use the gene encoding CD40L in an effort to promote a Th 1 response and control the destructive tissue inflammatory reaction. We demonstrate that co-injection of plasm ids encoding gp63 and CD40L resulted in a considerable amelioration of the disease outcome in 60% of mice, which was dependent on the concurrent injection of the truncated gp63 gene. Tissue inflammatory reaction was considerably controlled and there was a parallel delay in the initiation of the necrotic process.
Collectively, our results suggest that administration of a plasmid encoding CD40L has a beneficial outcome when given together with a plasmid encoding a secreted form of gp63, in terms of the reduction of the disfiguring tissue inflammatory reaction to the parasite challenge. Preliminary results support that this is accompanied by an enhanced Thl immune response. We are currently addressing the use of the CD40L-encoding plasmid with the membrane-bound form of gp63. The use of the truncated form of gp63 by itself is problematic, since it is associated with an exacerbation of inflammatory lesions.
